We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+43.4%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$101M
AUM Growth
–
Cap. Flow
+$84.4M
Cap. Flow %
83.47%
Top 10 Hldgs %
42.21%
Holding
52
New
52
Increased
–
Reduced
–
Closed
–

Top Buys

Rank Stock Value
1
RDY icon
Dr. Reddy's Laboratories
RDY
+$6.02M
2
LLY icon
Eli Lilly
LLY
+$5.66M
3
CI icon
Cigna
CI
+$4.47M
4
GPCR icon
Structure Therapeutics
GPCR
+$3.9M
5
IMGN
Immunogen Inc
IMGN
+$3.72M

Top Sells

No sells this quarter

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
TARS icon
26
Tarsus Pharmaceuticals
TARS
$2.6B
$1.71M 1.69%
+84,400
New +$1.41M
STTK icon
27
Shattuck Labs
STTK
$687M
$1.59M 1.57%
+223,300
New +$609K
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$122B
$1.59M 1.57%
+3,900
New +$1.44M
IMTX icon
29
Immatics
IMTX
$1.26B
$1.37M 1.35%
+129,900
New +$1.2M
PRTA icon
30
Prothena Corp
PRTA
$440M
$1.32M 1.31%
+36,384
New +$1.4M
GERN icon
31
Geron
GERN
$860M
$1.28M 1.27%
+607,500
New +$1.18M
TSHA icon
32
Taysha Gene Therapies
TSHA
$1.69B
$1.23M 1.21%
+693,300
New +$1.38M
MGNX icon
33
MacroGenics
MGNX
$240M
$1.21M 1.2%
+125,900
New +$870K
NTRA icon
34
Natera
NTRA
$38.6B
$1.17M 1.16%
+18,650
New +$932K
IGMS
35
DELISTED
IGM Biosciences
IGMS
$1.13M 1.11%
+135,596
New +$787K
CABA icon
36
Cabaletta Bio
CABA
$444M
$1.06M 1.05%
+46,700
New +$785K
MRTX
37
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$934K 0.92%
+15,896
New +$894K
PLRX icon
38
Pliant Therapeutics
PLRX
$65.6M
$898K 0.89%
+49,580
New +$754K
SAGE
39
DELISTED
Sage Therapeutics
SAGE
$764K 0.76%
+35,257
New +$699K
SWAV
40
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$762K 0.75%
+4,000
New +$756K
TVTX icon
41
Travere Therapeutics
TVTX
$5.33B
$755K 0.75%
+83,987
New +$612K
PACB icon
42
Pacific Biosciences
PACB
$460M
$739K 0.73%
+75,300
New +$616K
ESTA icon
43
Establishment Labs
ESTA
$2.75B
$715K 0.71%
+27,600
New +$808K
STRO icon
44
Sutro Biopharma
STRO
$411M
$659K 0.65%
+15,360
New +$487K
EYPT icon
45
EyePoint Inc
EYPT
$1.08B
$610K 0.6%
+26,400
New +$295K
MLTX icon
46
MoonLake Immunotherapeutics
MLTX
$1.62B
$588K 0.58%
+9,744
New +$502K
PROC
47
DELISTED
Procaps Group, S.A. Ordinary Shares
PROC
$516K 0.51%
+126,901
New +$370K
APLS
48
DELISTED
Apellis Pharmaceuticals
APLS
$434K 0.43%
+7,249
New +$368K
GRCL
49
DELISTED
Gracell Biotechnologies Inc. American Depositary Shares
GRCL
$411K 0.41%
+40,974
New +$186K
YARW
50
Yarrow Bioscience, Inc. Common Stock
YARW
$22M
$275K 0.27%
+2,362
New +$368K
1
2
3

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
EWM
Evergreen Wealth Management Williamston, Michigan $194M AUM 13.93% 1-Year Est. Return

Exome Asset Management's Q4 2023 Portfolio in Review

Q4 2023 is the first quarter with a 13F filing on record for Exome Asset Management, which disclosed 52 positions worth $101M. Its ten largest holdings account for 42% of the portfolio.

Its largest position is Dr. Reddy's Laboratories: 450,000 shares worth $6.26M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets.

  • Exome Asset Management's largest Q4 2023 buy was Dr. Reddy's Laboratories: 450,000 shares worth $6.26M.
  • Exome Asset Management's ten largest holdings make up 42% of its $101M portfolio in Q4 2023.
  • Exome Asset Management disclosed 52 positions in Q4 2023, its first 13F filing on record.

Based on Exome Asset Management's 13F filing for Q4 2023, filed 15 Feb 2024.